| ［1］ |
Sun K，Zhang B，Lei S，et al. Incidence，mortality，and disability-adjusted life years of female breast cancer in China，2022［J］. Chin Med J，2024，137（20）：2429-2436.
|
| ［2］ |
Han B，Zheng R，Zeng H，et al. Cancer incidence and mortality in China，2022［J］. J Natl Cancer Cent，2024，4（1）：47-53.
|
| ［3］ |
Tao X，Li T，Gandomkar Z，et al. Incidence，mortality，survival，and disease burden of breast cancer in China compared to other developed countries［J］. Asia Pac J Clin Oncol，2023，19（6）：645-654.
|
| ［4］ |
Long Z，Qiu Y，Long ZH，et al. Epidemiology of breast cancer in Chinese women from 1990 to 2021： a systematic analysis and comparison with the global burden［J］. BMC Cancer，2025，25（1）：3.
|
| ［5］ |
Lei S，Zheng R，Zhang S，et al. Breast cancer incidence and mortality in women in China： temporal trends and projections to 2030［J］. Cancer Biol Med，2021，18（3）：900-909.
|
| ［6］ |
Fisher B，Bryant J，Wolmark N，et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer［J］. J Clin Oncol，2023，41（10）： 1795-1808.
|
| ［7］ |
Early Breast Cancer Trialists' Collaborative Group （EBCTCG）. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer： meta-analysis of individual patient data from ten randomised trials［J］. Lancet Oncol，2018，19（1）：27-39.
|
| ［8］ |
Shah M，Osgood CL，Amatya AK，et al. FDA approval summary： pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer［J］. Clin Cancer Res，2022，28（24）：5249-5253.
|
| ［9］ |
I-SPY2 Trial Consortium，Yee D，DeMichele AM，et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer： three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial［J］. JAMA Oncol，2020，6（9）： 1355-1362.
|
| ［10］ |
Samiei S，Simons JM，Engelen SME，et al. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease： a systematic review and meta-analysis［J］. JAMA Surg，2021，156（6）：e210891.
|
| ［11］ |
Yau C，Osdoit M，van der Noordaa M，et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer： a multicentre pooled analysis of 5161 patients［J］. Lancet Oncol，2022，23（1）： 149-160.
|
| ［12］ |
Korde LA，Somerfield MR，Carey LA，et al. Neoadjuvant chemotherapy，endocrine therapy，and targeted therapy for breast cancer： ASCO guideline［J］. J Clin Oncol，2021，39（13）： 1485-1505.
|
| ［13］ |
Papakonstantinou A，Gonzalez NS，Pimentel I，et al. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy： a systematic review and meta-analysis［J］. Cancer Treat Rev，2022，104：102362.
|
| ［14］ |
Mo Z，Yang M，Zhu Z，et al. Multiomic integration reveals subtype-specific predictors of neoadjuvant treatment response in breast cancer［J］. Sci Adv，2025，11（27）：eadu1521.
|
| ［15］ |
Surov A，Pech M，Meyer HJ，et al. Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study［J］. Cancer Imaging，2022，22（1）：68.
|
| ［16］ |
Provenzano E，Bossuyt V，Viale G，et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer： recommendations from an international working group［J］. Mod Pathol，2015，28（9）：1185-1201.
|
| ［17］ |
Abubakar M，Figueroa J，Ali HR，et al. Combined quantitative measures of ER，PR，HER2，and KI67 provide more prognostic information than categorical combinations in luminal breast cancer［J］. Mod Pathol，2019，32（9）：1244-1256.
|
| ［18］ |
El Bairi K，Haynes HR，Blackley E，et al. The tale of TILs in breast cancer： a report from The International Immuno-Oncology Biomarker Working Group［J］. NPJ Breast Cancer，2021，7（1）：150.
|
| ［19］ |
Shu D，Shen M，Li K，et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy［J］. Ann Med，2022，54（1）：2581-2597.
|
| ［20］ |
Zhang Z，Zhao X，Chen J. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2-early breast cancer：a systematic review and meta-analysis［J］. Front Pharmacol，2024，15：1438288.
|
| ［21］ |
Schmid P，Cortes J，Dent R，et al. Event-free survival with pembrolizumab in early triple-negative breast cancer［J］. N Engl J Med，2022，386（6）：556-567.
|
| ［22］ |
Wang Y，Feng Z，Liu X，et al. Evaluation of early response in association with pathological response in patients with breast cancer receiving neoadjuvant chemotherapy［J］. J Clin Oncol，2024，42（16_suppl）： e12628.
|
| ［23］ |
Salehifar E，Janbabaei G，Alipour A，et al. Taxane-induced peripheral neuropathy and quality of life in breast cancer patients［J］. J Oncol Pharm Pract，2020，26（6）： 1421-1428.
|
| ［24］ |
Davudov MM，Harirchi I，Amiraliyev N，et al. The azeri version of European organization for research and treatment of cancer core quality of life questionnaire （EORTC QLQ-C30）： translation and validation［J］. Asian Pac J Cancer Prev，2020，21（1）： 267-271.
|
| ［25］ |
Parsons HA，Blewett T，Chu X，et al. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030［J］. Ann Oncol，2023，34（10）： 899-906.
|
| ［26］ |
Hulikal N，Gajjala SR，Kalawat T，et al. Predicting response to neoadjuvant chemotherapy using 18F FDG PET-CT in patients with locally advanced breast cancer［J］. Asian Pac J Cancer Prev，2020，21（1）： 93-98.
|
| ［27］ |
Wang F，Wang Y，Xiong B，et al. Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response （NeoPaTHer）： efficacy，safety and biomarker analysis of a prospective，multicentre，response-adapted study［J］. Signal Transduct Target Ther，2025，10（1）：45.
|
| ［28］ |
Mohamed RM，Panthi B，Adrada BE，et al. Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer［J］. Sci Rep，2024，14（1）： 16073.
|
| ［29］ |
Bhardwaj PV，Mason H，Kaufman SA，et al. Outcomes of a multidisciplinary team in the management of patients with early-stage breast cancer undergoing neoadjuvant chemotherapy at a community cancer center［J］. Curr Oncol，2023，30（5）： 4861-4870.
|
| ［30］ |
Huang X，Shi Z，Mai J，et al. An MRI-based scoring system for preoperative prediction of axillary response to neoadjuvant chemotherapy in node-positive breast cancer： a multicenter retrospective study［J］. Acad Radiol，2023，30（7）： 1257-1269.
|
| ［31］ |
Xiang H，Xin L，Ye J，et al. A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems （CSBrS-026）［J］. Chin J Cancer Res，2023，35（6）： 702-712.
|
| ［32］ |
Lopes AD，Galdino NAL，Figueiredo AB，et al. Systemic immune mediators reflect tumour-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer［J］. Immunology，2023，169（2）： 229-241.
|
| ［33］ |
Jinga DC，Jinga MR，Miron A，et al. Pathological response and survival after neoadjuvant therapy for Her-2 positive breast cancer［J］. Chirurgia （Bucur），2021，116（2 Suppl）：91-97.
|
| ［34］ |
Roussot N，Constantin G，Desmoulins I，et al. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy［J］. Eur J Cancer，2024，202： 114037.
|
| ［35］ |
Hasegawa Y，Matsubara N，Kogawa T，et al. Neo-bioscore in guiding post-surgical therapy in patients with triple-negative breast cancer who received neoadjuvant chemotherapy［J］. In Vivo，2021，35（2）： 1041-1049.
|
| ［36］ |
Oner I，Turkel A，Karacin C，et al. Adjuvant capecitabine after neoadjuvant chemotherapy in triple negative breast cancer with lymph node metastasis［J］. J Coll Physicians Surg Pak，2023，33（9）： 1012-1018.
|
| ［37］ |
De Rose F，Meduri B，De Santis MC，et al. Rethinking breast cancer follow-up based on individual risk and recurrence management［J］.Cancer Treat Rev，2022，109： 102434.
|
| ［38］ |
Loibl S，André F，Bachelot T，et al. Early breast cancer： ESMO Clinical Practice Guideline for diagnosis，treatment and follow-up［J］. Ann Oncol，2024，35（2）： 159-182.
|
| ［39］ |
Khan MI. Management of bone loss due to endocrine therapy during cancer treatment［J］. Osteoporos Int，2023，34（4）： 671-680.
|
| ［40］ |
O'Hea EL，Creamer S，Flahive JM，et al. Survivorship care planning，quality of life，and confidence to transition to survivorship： a randomized controlled trial with women ending treatment for breast cancer［J］. J Psychosoc Oncol，2022，40（5）： 574-594.
|
| ［41］ |
Jagsi R，Mason G，Overmoyer BA，et al. Inflammatory breast cancer defined： proposed common diagnostic criteria to guide treatment and research［J］. Breast Cancer Res Treat，2022，192（2）： 235-243.
|
| ［42］ |
Boussen H，Berrazaga Y，Kullab S，et al. Inflammatory breast cancer： Epidemiologic data and therapeutic results［J］. Int Rev Cell Mol Biol，2024，384： 1-23.
|
| ［43］ |
Mouabbi JA，Hassan A，Lim B，et al. Invasive lobular carcinoma： an understudied emergent subtype of breast cancer［J］. Breast Cancer Res Treat，2022，193（2）： 253-264.
|
| ［44］ |
Cserni G. Invasive lobular carcinoma of the breast： we diagnose it，but do we know what it is？［J］. Pathologica，2024，116（5）： 273-284.
|
| ［45］ |
Djerroudi L，Cabel L，Bidard FC，et al. Invasive lobular carcinoma of the breast： toward tailoring therapy？［J］. J Natl Cancer Inst，2022，114（11）： 1434-1436.
|
| ［46］ |
Zupancic M，Näsman A，Friesland S，et al. Adenoid cystic carcinoma，clinical presentation，current treatment and approaches towards novel therapies［J］. Anticancer Res，2024，44（4）： 1325-1334.
|
| ［47］ |
Thomas HR，Hu B，Boyraz B，et al. Metaplastic breast cancer： a review［J］. Crit Rev Oncol Hematol，2023，182： 103924.
|
| ［48］ |
Hampe ME，Rhoton-Vlasak AS. Fertility preservation in breast cancer with case-based examples for guidance［J］. J Assist Reprod Genet，2020，37（3）： 717-729.
|
| ［49］ |
Razeti MG，Soldato D，Arecco L，et al. Approaches to fertility preservation for young women with breast cancer［J］. Clin Breast Cancer，2023，23（3）： 241-248.
|
| ［50］ |
AlFehaid M. Male breast cancer （MBC） - a review［J］. Pol Przegl Chir，2023，95（6）： 24-30.
|
| ［51］ |
Boere I，Lok C，Poortmans P，et al. Breast cancer during pregnancy： epidemiology，phenotypes，presentation during pregnancy and therapeutic modalities［J］. Best Pract Res Clin Obstet Gynaecol，2022，82： 46-59.
|